CLAIMS

1. Use of brincidofovir, a pharmaceutically acceptable salt thereof, or a solvate thereof in the manufacture of a medicament for the treatment of a malignant tumor, wherein a subject of the treatment has a malignant tumor with low TLE1 expression.

2. The use according to claim 1, wherein the malignant tumor has low TLE1 expression and has high sensitivity to brincidofovir, a pharmaceutically acceptable salt thereof, or a solvate thereof.

3. The use according to claim 1 or 2, wherein the medicament suppresses proliferation of the malignant tumor cells.

4. The use according to any one of claims 1 to 3, wherein the malignant tumor is a hematologic cancer with low TLE1 expression.

5. The use according to any one of claims 1 to 4, wherein the malignant tumor is a lymphoma with low TLE1 expression.

6. The use according to any one of claims 1 to 5, wherein the malignant tumor is an NK/T-cell lymphoma with low TLE1 expression or a T-cell lymphoma with low TLE1 expression.

7. The use according to any one of claims 1 to 6, wherein the brincidofovir, a pharmaceutically acceptable salt thereof, or a solvate thereof is brincidofovir.

8. Use of brincidofovir, a pharmaceutically acceptable salt thereof, or a solvate thereof in the manufacture of a medicament for the treatment of a malignant tumor, wherein a subject of the treatment is a subject identified based on an expression level of TLE1 as an indicator.

9. The use according to claim 8, wherein the brincidofovir, a pharmaceutically acceptable salt thereof, or a solvate thereof is brincidofovir.

10. The use according to claim 8 or 9, wherein the subject is a subject predicted to have high sensitivity to brincidofovir, a pharmaceutically acceptable salt thereof, or a solvate thereof, based on an expression level of TLE1 as an indicator.

11. The use according to any one of claims 8 to 10, wherein the subject is a subject identified based on an expression level of TLE1 in malignant tumor cells of the subject as an indicator.

12. The use according to any one of claims 8 to 11, wherein the treatment comprises testing an expression level of TLE1 of the subject.

13. The use according to any one of claims 8 to 12, wherein the treatment comprises identifying a subject having high sensitivity to brincidofovir, a pharmaceutically acceptable salt thereof, or a solvate thereof, based on an expression level of TLE1 as an indicator.

14. The use according to any one of claims 8 to 13, wherein the subject is a subject diagnosed as having a malignant tumor with low TLE1 expression.

15. The use according to any one of claims 8 to 13, wherein the subject is a subject diagnosed as having a malignant tumor with high TLE1 expression.

16. The use according to any one of claims 8 to 15, wherein the malignant tumor is a MYC-positive malignant tumor.

17. The use according to any one of claims 8 to 16, wherein the malignant tumor is a hematologic cancer.

18. The use according to any one of claims 8 to 17, wherein the malignant tumor is a lymphoma.

19. The use according to any one of claims 8 to 18, wherein the malignant tumor is an NK/T-cell lymphoma, a B-cell lymphoma, or a T-cell lymphoma.

20. The use according to claim 14, wherein the malignant tumor is an NK/T-cell lymphoma.

21. The use according to claim 14, wherein the malignant tumor is a T-cell lymphoma.

22. The use according to claim 15, wherein the malignant tumor is a B-cell lymphoma.